Wockhardt Ltd's Q4FY25 Quarter Results
- 30 May 2025
Result Summary
- Wockhardt Ltd reported a 3.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 6.2%.
- Its expenses for the quarter were up by 31.9% QoQ and 15.7% YoY.
- The net profit decreased 985.0% QoQ and decreased 25.3% YoY.
- The earnings per share (EPS) of Wockhardt Ltd declined at 11.6 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 754.00 | 729.00 | 710.00 | 3.4% | 6.2% |
Total Expenses | 934.00 | 708.00 | 807.00 | 31.9% | 15.7% |
Profit Before Tax | -180.00 | 21.00 | -193.00 | -957.1% | -6.7% |
Tax | -3.00 | 1.00 | 44.00 | -400.0% | -106.8% |
Profit After Tax | -177.00 | 20.00 | -237.00 | -985.0% | -25.3% |
Earnings Per Share | -11.60 | 0.90 | -14.40 | -1388.9% | -19.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Wockhardt Ltd is a global pharmaceutical and biotechnology company headquartered in India. It operates in the healthcare sector, primarily focusing on the development and manufacturing of a broad range of pharmaceutical and biopharmaceutical products. The company is known for its innovative drug delivery systems and has a strong presence in both domestic and international markets. Wockhardt Ltd engages in the production of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and biosimilars. Recent developments include its efforts in producing vaccines and expanding its global footprint through strategic partnerships. Specific recent developments or changes in the company’s strategic direction are not available in the data provided.
Revenue
In the fourth quarter of the fiscal year 2025 (Q4FY25), Wockhardt Ltd reported a total income of ₹754 crores. This represents a quarter-over-quarter (QoQ) increase of 3.4% from ₹729 crores in Q3FY25. On a year-over-year (YoY) basis, total income grew by 6.2% from ₹710 crores in Q4FY24. The steady increase in revenue suggests a positive trend over both the previous quarter and the corresponding quarter of the previous year. The growth in income could be attributed to increased sales volumes, new product launches, or enhanced market penetration, although specific drivers are not detailed in the provided data.
Profitability
Wockhardt Ltd’s profitability metrics for Q4FY25 indicate a challenging financial period. The company recorded a loss before tax of ₹180 crores, compared to a profit before tax of ₹21 crores in Q3FY25, marking a significant QoQ decline. Year-over-year, the loss before tax was slightly reduced from a loss of ₹193 crores in Q4FY24. The tax expense for Q4FY25 was recorded as a negative ₹3 crores, compared to ₹1 crore in Q3FY25 and ₹44 crores in Q4FY24, reflecting a considerable change. The profit after tax for Q4FY25 was a loss of ₹177 crores, a substantial decrease from the profit of ₹20 crores in the previous quarter. The YoY comparison shows an improvement from a loss of ₹237 crores in Q4FY24. Earnings per share (EPS) were noted as negative ₹11.60, showing a significant decline from ₹0.90 in Q3FY25 and an improvement from negative ₹14.40 in Q4FY24.
Operating Metrics
The operating metrics for Wockhardt Ltd in Q4FY25 reveal a notable increase in total expenses, which rose to ₹934 crores from ₹708 crores in Q3FY25, marking a QoQ increase of 31.9%. Year-over-year, the expenses increased by 15.7% from ₹807 crores in Q4FY24. This increase in expenses might reflect higher costs associated with production, research and development, or other operational areas. The significant rise in expenses, coupled with the increase in total income, highlights an area of financial performance that impacts overall profitability. These metrics provide insight into the operational challenges and potential areas for cost optimization, although specific operational initiatives are not detailed in the data provided.